SURWEY real-world study of solriamfetol: initiation, titration, safety, efficacy, and follow-up experience for patients with obstructive sleep apnea in Germany [PDF]
Purpose Solriamfetol is approved for use in the European Union to treat excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA). SURWEY characterized real-world evidence regarding physician initiation and titration strategies
Benes, Heike +6 more
core +1 more source
Cataplexy versus Pseudoseizure : A Case Study [PDF]
, 2020 Cataplexy is frequently misdiagnosed as pseudo seizures. This case study about a young patient shows the necessary steps needed to accurately diagnose and treat cataplexy as well as understand the differences between narcolepsy Type I and Type ...
Atassi, Katherine, Atassi, Sammar
core +2 more sources
Work productivity and activity impairment in patients with narcolepsy type 1 [PDF]
, 2023 The aim of this study was to assess work productivity and activity impairments and to explore their association with excessive daytime sleepiness, body mass index (BMI), depression, and anxiety in patients with narcolepsy type 1.
Bassi, Chiara +7 more
core +2 more sources
0756 Preclinical Pharmacology of Solriamfetol: Potential Mechanisms for Wake Promotion
Sleep, 2022 Abstract Introduction Solriamfetol is a wake-promoting agent (WPA) approved for the treatment of excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea. The wake-promoting mechanism of solriamfetol may result from dopamine and norepinephrine reuptake inhibition ...
Hema Gursahani +5 more
openaire +1 more source
Use of empagliflozin as an adjuvant treatment for obstructive sleep apnea for a patient who has not seen a physician in over 40 years [PDF]
A clinical decision report using: Neeland IJ, Eliasson B, Kasai T, et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care. 2020;43(12):3007-
Demko, Andrew
core +2 more sources
SLC6 neurotransmitter transporter family in GtoPdb v.2023.1 [PDF]
, 2023 Members of the solute carrier family 6 (SLC6) of sodium- and (sometimes chloride-) dependent neurotransmitter transporters [32, 2, 23, 75] are primarily plasma membrane located and may be divided into four subfamilies that transport monoamines, GABA ...
Bröer, Stefan, Rudnick, Gary
core +2 more sources
Tratamento da síndrome da apneia obstrutiva do sono: revisão da literatura [PDF]
, 2022 The objective of this review was to identify the main treatments available for obstructive sleep apnea syndrome. A search for information was carried out in Pubmed, BVS, Science Direct, Scopus, Web of Science, Scielo, Ovid, Lilacs, Research Gate, and ...
Idrovo Rojas, Trudy +3 more
core +3 more sources
Recent advances in treatment for narcolepsy
Therapeutic Advances in Neurological Disorders, 2019 Narcolepsy type 1 (NT1) is a chronic orphan disorder, caused by the selective and irreversible loss of hypocretin/orexin (ORX) neurons, by a probable autoimmune process.
Lucie Barateau, Yves Dauvilliers
doaj +1 more source
Adrenoceptors: A Focus on Psychiatric Disorders and Their Treatments [PDF]
, 2023 Research into the involvement of adrenoceptor subtypes in the cause(s) of psychiatric disorders is particularly challenging. This is partly because of difficulties in developing animal models that recapitulate the human condition but also because no ...
Heal, David J, Stanford, S Clare
core
0763 Effects Of Solriamfetol On Driving Performance In Participants With Narcolepsy [PDF]
Sleep, 2020 Abstract Introduction Patients with narcolepsy have an increased risk of automobile accidents. Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, is approved in the US (Sunosi®) for adults with excessive daytime sleepiness (EDS) associated with narcolepsy (75-150 mg/day). This study evaluated
Vinckenbosch, F. +8 more
openaire +2 more sources